The expression levels of vimentin were used as a prognostic indicator for the treatment efficacy for patients with NSCLC with erlotinib, erlotinib/bevacizumab (EB) or cisplatin/gemcitabine/bevacizumab (PGB) (Richardson et al., 2012; Villalobos et al., 2019). The gene discussed is VIM; the disease is non-small cell lung carcinoma.